[Mexidol potentiates antiparkinsonian effect of L-DOPA in MPTP-induced parkinsonism model].
Preliminary peroral administration of mexidol into mice with (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)-induced parkinsonism model prevented the formation of malonaldehyde in striatum. In combination with small doses of L-DOPA (2-mg/kg), mexidol decreased oligokinesia and muscular rigidity manifestations and increased the levels of dopamine and its metabolites--dioxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in striatum. The combined (mexidol + L-DOPA) drug administration produced a 3-5 h increase in the time of the parkinsonism syndrome inhibition as compared to that upon the administration of a greater L-DOPA dose (100 mg/kg) without mexidol. It is suggested that mexidol, possessing antioxidant properties, is capable of preventing the damage and loss of the nigrostriatial dopaminergic neurons.
Kucherianu
V G
VG
Department of Nervous System Pathology, Institute of General Pathology and Pathophysiology, Russian Academy of Medical Sciences, Baltiiskaya ul. 8, Moscow, 125315 Russia.
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D003342:Corpus Striatum / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D015259:Dopamine Agents; D004357:Drug Synergism; D006719:Homovanillic Acid / Q000378:metabolism; D007980:Levodopa / Q000627:therapeutic use*; D015227:Lipid Peroxidation; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D010847:Picolines / Q000627:therapeutic use*
D000975:Antioxidants; D015259:Dopamine Agents; D010847:Picolines; D015102:3,4-Dihydroxyphenylacetic Acid; C070020:emoxypine succinate; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine; D006719:Homovanillic Acid